カテゴリ： Grand View Research, 世界, 医療/バイオ

肺動脈高血圧の世界市場：薬物クラス別（プロスタサイクリン＆プロスタサイクリン類似体、ERA、PDE-5）

◆英語タイトル：Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5), And Segment Forecasts, 2020 - 2027
◆商品コード：GV20MY067
◆発行会社（リサーチ会社）：Grand View Research
◆発行日：2020年3月12日
◆ページ数：140
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥642,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥750,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥966,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。
本調査レポートでは、肺動脈高血圧の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、薬物クラス別（プロスタサイクリン＆プロスタサイクリン類似体、ERA、PDE-5）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東及びアフリカ）分析、企業概要などの構成でお届けいたします。
・調査手法・範囲
・エグゼクティブサマリー
・市場要因・動向・範囲
・肺動脈高血圧の世界市場：薬物クラス別（プロスタサイクリン＆プロスタサイクリン類似体、ERA、PDE-5）
・肺動脈高血圧の世界市場：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東及びアフリカ）
・企業概要
【レポートの概要】

The global pulmonary arterial hypertension market size is expected to reach USD 9.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 5.6% over the forecast period. Increasing prevalence rates of pulmonary arterial hypertension (PAH) and government support for the development of orphan drugs drive the market growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80 percent of the population aged 65 and above have at least one chronic condition such as high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease.

Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983, are also anticipated to support the market for treatment drugs for PAH. These acts play a significant role in promoting the ethical usage and distribution of orphan drugs. The development of orphan drugs is promoted by the National Organization of Rare Disorders.

Robust drug pipeline and new product combinations awaiting approval or launch are anticipated to increase the PAH market competitiveness over the forecast period. In September 2019, Acceleron Pharma, a leading biopharmaceutical company, received FDA orphan drug designation for sotatercept for the treatment of pulmonary arterial hypertension.

Further key findings from the report suggest:

• Prostacyclin and its analogs for treating PAH are projected to show lucrative growth over the forecast period. The sales of these drugs are anticipated to increase due to the growing use of oral prostacyclin agents

• North America dominated the PAH market with a share of over 55.0% in 2019. This is attributed to the well-established infrastructure for the development and distribution of high-quality therapies and the availability of reimbursement for PAH therapies

• Asia Pacific is estimated to register the highest CAGR of more than 6.0% over the forecast period due to its huge population base, rapid economic development, and improving healthcare system. Moreover, the high burden of diseases such as HIV in the region contribute to the development of PAH

• The major players in the pulmonary arterial hypertension market that offer treatment solutions for PAH include GlaxoSmithKline plc; Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.); United Therapeutics Corporation; Pfizer, Inc.; and Gilead Sciences, Inc. The market is consolidated and competitive in nature. The players enjoy the benefit of high entry barriers to other firms due to high price interdependency

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Drug
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective – 1:
1.10.2 Objective – 2:
1.10.3 Objective – 3:
1.10.4 Objective – 4:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Business Segment Trends
2.3.1 Service Business Analysis
2.3.2 Application Business Analysis
2.3.3 Regional Business Analysis
2.4 Competitive Insights
Chapter 3 Pulmonary Arterial Hypertension Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, By Stage
3.3.1 Registration Phase
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List Of Key End-Users, By Region / By Product / By Country
3.6 Regulatory Framework
3.6.1 Reimbursement Framework
3.6.1.1 Therapy Cost
3.6.1.2 Therapy Monitoring Cost
3.6.1.3 Average Selling Price
3.6.2 Standards & Compliances
3.7 Market Variable Analysis
3.7.1 Market Driver Analysis
3.7.1.1 Incidents Of Pulmonary Arterial Hypertension (PAH)
3.7.1.2 Growing Geriatric Population
3.7.1.3 Government Support For Development Of Orphan Drugs
3.7.2 Market Restraint Analysis
3.7.2.1 Patent Expiration Of Key Molecules
3.7.3 Industry Challenges
3.8 Pulmonary Arterial Hypertension Market: Analysis Tools
3.8.1 Porter’s Five Forces Analysis
3.8.1.1 Supplier Power: Low
3.8.1.2 Buyer Power: Moderate
3.8.1.3 Substitution Threat: Moderate
3.8.1.4 Threat From New Entrant: Moderate
3.8.1.5 Competitive Rivalry: High
3.8.2 Pestel Analysis
3.8.3 Major Deals & Strategic Alliances Analysis
3.8.4 Market Entry Strategies
Chapter 4 Pulmonary Arterial Hypertension Market: Drug Class Segment Analysis
4.1 Pulmonary Arterial Hypertension Market: Definition & Scope
4.2 Pulmonary Arterial Hypertension: Market Share Analysis, 2019 & 2027
4.3 Prostacyclin and Prostacyclin Analogs
4.3.1 Prostacyclin and Prostacyclin Analogs market, 2016 – 2027 (USD Million)
4.4 Soluble Guanylate Cyclase (SGC) Stimulators
4.4.1 Soluble Guanylate Cyclase (SGC) Stimulators market, 2016 – 2027 (USD Million)
4.5 Endothelin Receptor Antagonists (ERAs)
4.5.1 Endothelin Receptor Antagonists (ERAS) market, 2016 – 2027 (USD Million)
4.6 Phosphodiesterase 5 (PDE-5)
4.6.1 Phosphodiesterase 5 (PDE-5) market, 2016 – 2027 (USD Million)
Chapter 5 Pulmonary Arterial Hypertension Market: Regional Analysis
5.1 Pulmonary Arterial Hypertension Market: Definition & Scope
5.2 Regional Market Snapshot
5.3 Regional Market Share and Leading Players, 2018
5.3.1 North America
5.3.2 Europe
5.3.3 Asia Pacific
5.3.4 Latin America
5.3.5 Middle East & Africa
5.4 Pulmonary Arterial Hypertension Market: Market Share Analysis, 2018 & 2027
5.5 North America
5.5.1 North America Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.5.2 U.S.
5.5.2.1 U.S. Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.5.3 Canada
5.5.3.1 Canada Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.6 Europe
5.6.1 Europe Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.6.2 U.K.
5.6.2.1 U.K. Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.6.3 Germany
5.6.3.1 Germany Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.6.4 France
5.6.4.1 France Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.6.5 Italy
5.6.5.1 Italy Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.6.6 Spain
5.6.6.1 Spain Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.7 Asia Pacific
5.7.1 Asia Pacific Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.7.2 Japan
5.7.2.1 Japan Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.7.3 China
5.7.3.1 China Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.7.4 Australia
5.7.4.1 Australia Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.7.5 South Korea
5.7.5.1 South Korea Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.7.6 India
5.7.6.1 India Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.8 Latin America
5.8.1 Latin America Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.8.2 Brazil
5.8.2.1 Brazil Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.8.3 Mexico
5.8.3.1 Mexico Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.8.4 Argentina
5.8.4.1 Argentina Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.9 MEA
5.9.1 MEA Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.9.2 South Africa
5.9.2.1 South Africa Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.9.3 Saudi Arabia.
5.9.3.1 Saudi Arabia Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
5.9.4 UAE
5.9.4.1 UAE Pulmonary Arterial Hypertension market, 2016 – 2027 (USD Million)
Chapter 6 Company Profiles
6.1 Company Profiles
6.1.1 Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.)
6.1.1.1 Company overview
6.1.1.2 Financial performance
6.1.1.3 Product benchmarking
6.1.1.4 Strategic initiatives
6.1.2 Gilead Sciences, Inc.
6.1.2.1 Company overview
6.1.2.2 Financial Performance
6.1.2.3 Product benchmarking
6.1.2.4 Strategic initiatives
6.1.3 United Therapeutics Corporation
6.1.3.1 Company overview
6.1.3.2 Financial performance
6.1.3.3 PAH Global Sale
6.1.3.4 Product benchmarking
6.1.3.5 Strategic initiatives
6.1.4 Novartis International AG
6.1.4.1 Company overview
6.1.4.2 Financial Performance
6.1.4.3 Product benchmarking
6.1.4.4 Strategic initiatives
6.1.5 GlaxoSmithKline Plc. (GSK)
6.1.5.1 Company overview
6.1.5.2 Financial performance
6.1.5.3 Product benchmarking
6.1.6 Pfizer, Inc.
6.1.6.1 Company overview
6.1.6.2 Product benchmarking
6.1.7 Dong-A ST Co., Ltd.
6.1.7.1 Company overview
6.1.7.2 Financial performance
6.1.7.3 Product benchmarking
6.1.7.4 Strategic initiatives
6.1.8 Merck Sharp & Dohme Corp.
6.1.8.1 Company overview
6.1.8.2 Financial Performance
6.1.8.3 Product benchmarking
6.1.8.4 Strategic initiatives
6.1.9 Bayer HealthCare
6.1.9.1 Company overview
6.1.9.2 Financial Performance
6.1.9.3 Product benchmarking
6.1.9.4 Strategic initiatives
6.1.10 Arena Pharmaceuticals
6.1.10.1 Company overview
6.1.10.2 Financial performance
6.1.10.3 Product benchmarking
Chapter 7 KOL Commentary
7.1 Key Insights
7.2 KOL Views
Chapter 8 Recommendations

List of Tables

Table 1 List of abbreviation
Table 2 Vendor landscape, 2019
Table 3 Fire alarm and detection market, 2016 - 2027 (USD Million)
Table 4 Fire detectors market, 2016 - 2027 (USD Million)
Table 5 Fire alarms market, 2016 - 2027 (USD Million)
Table 6 Flame detectors market, 2016 - 2027 (USD Million)
Table 7 Smoke detectors market, 2016 - 2027 (USD Million)
Table 8 Heat detectors market, 2016 - 2027 (USD Million)
Table 9 Audible alarms market, 2016 - 2027 (USD Million)
Table 10 Visual alarms market, 2016 - 2027 (USD Million)
Table 11 Manual call-points market, 2016 - 2027 (USD Million)
Table 12 Commercial fire alarm and detection market, 2016 - 2027 (USD Million)
Table 13 Industrial fire alarm and detection market, 2016 - 2027 (USD Million)
Table 14 Residential fire alarm and detection market, 2016 - 2027 (USD Million)
Table 15 North America fire alarm and detection market, by country, 2016 - 2027 (USD Million)
Table 16 North America fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 17 North America fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 18 North America fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 19 North America fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 20 U.S. fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 21 U.S. fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 22 U.S. fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 23 U.S. fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 24 Canada fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 25 Canada fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 26 Canada fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 27 Canada fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 28 Europe fire alarm and detection market, by country, 2016 - 2027 (USD Million)
Table 29 Europe fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 30 Europe fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 31 Europe fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 32 Europe fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 33 Germany fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 34 Germany fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 35 Germany fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 36 Germany fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 37 U.K. fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 38 U.K. fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 39 U.K. fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 40 U.K. fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 41 Asia Pacific fire alarm and detection market, by country, 2016 - 2027 (USD Million)
Table 42 Asia Pacific fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 43 Asia Pacific fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 44 Asia Pacific fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 45 Asia Pacific fire alarm and detection, by application, 2016 - 2027 (USD Million)
Table 46 China fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 47 China fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 48 China fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 49 China fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 50 Japan fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 51 Japan fire alarm and detection, fire detectors by type, 2016 - 2027 (USD Million)
Table 52 Japan fire alarm and detection, fire alarms by type, 2016 - 2027 (USD Million)
Table 53 Japan fire alarm and detection, by application, 2016 - 2027 (USD Million)
Table 54 India fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 55 India fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 56 India fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 57 India fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 58 Latin America fire alarm and detection market, by country, 2016 - 2027 (USD Million)
Table 59 Latin America fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 60 Latin America fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 61 Latin America fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 62 Latin America fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 63 Brazil fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 64 Brazil fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 65 Brazil fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 66 Brazil fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 67 Mexico fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 68 Mexico fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 69 Mexico fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 70 Mexico fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Table 71 MEA fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Table 72 MEA fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Table 73 MEA fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Table 74 MEA fire alarm and detection market, by application, 2016 - 2027 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Fire alarm and detection market segmentation
Fig. 4 Fire alarm and detection market snapshot
Fig. 5 Fire alarm and detection market, 2016 - 2027 (USD Million)
Fig. 6 Fire alarm and detection market, by product, 2016 - 2027 (USD Million)
Fig. 7 Fire alarm and detection market, fire detectors by type, 2016 - 2027 (USD Million)
Fig. 8 Fire alarm and detection market, fire alarms by type, 2016 - 2027 (USD Million)
Fig. 9 Fire alarm and detection market, by application, 2016 - 2027 (USD Million)
Fig. 10 Fire alarm and detection market, by region, 2016 - 2027 (USD Million)
Fig. 11 Fire alarm and detection market: Value chain analysis
Fig. 12 Fire alarm and detection market penetration and growth prospect mapping
Fig. 13 Fire alarm and detection market : Key company analysis, 2019
Fig. 14 Fire alarm and detection market: PEST analysis
Fig. 15 Fire alarm and detection market: PORTER’s analysis
Fig. 16 Fire alarm and detection market: Product analysis
Fig. 17 Fire alarm and detection market: Fire detectors by type analysis
Fig. 18 Fire alarm and detection market: Fire alarms by type analysis
Fig. 19 Fire alarm and detection market: Application analysis
Fig. 20 Fire alarm and detection market: Regional analysis
Fig. 21 North America fire alarm and detection market - key takeaways
Fig. 22 Europe fire alarm and detection market - key takeaways
Fig. 23 Asia Pacific fire alarm and detection market - key takeaways
Fig. 24 Latin America fire alarm and detection market - key takeaways
Fig. 25 MEA fire alarm and detection market - key takeaways

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[肺動脈高血圧の世界市場：薬物クラス別（プロスタサイクリン＆プロスタサイクリン類似体、ERA、PDE-5）]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 眼科用医薬品の世界市場：薬物クラス別、疾患別、剤形別、投与経路別、製品タイプ別、地域別
    GV20MY062 / Grand View Research / 2020年2月18日 / 本調査レポートでは、眼科用医薬品の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、競争分析、薬物クラス別（抗アレルギー、抗VEGF剤、抗炎症、抗緑内障、その他）分析、疾患別（ドライアイ、眼アレルギー、緑内障、眼感染症、網膜疾患、ブドウ膜炎）分析、剤形別（ゲル、点眼液、カプセル剤、錠剤、点眼剤、軟膏）分析、投与経路別分析、製品種類別（処方薬、OTC薬）分析、地域別分析、企業概要などの構成でお届けいたします。 ・調査手法・範囲 ・エグゼクティブサマリー ・市場要因・動向・範囲 ・競争分析 ・眼科用医薬品の世界市場：薬物クラス別（抗アレルギー、抗VEGF剤、抗炎症、抗緑内障、その他） ・眼科用医薬品の世界市場：疾患別（ドライアイ、眼アレルギー、緑内障、眼感染症、網膜疾患、ブドウ膜炎） ・眼科用医薬品の世界市場：剤形別（ゲル、点眼液、カプセル剤、錠剤、点眼剤、軟膏） ・眼科用医薬品の世界市場：投与経路別 ・眼科用医薬品の世界市場：製品種類別（処方薬、OTC薬）...The global ophthalmic drugs market size is expected to reach USD 45.8 billion by 2027, registering a CAGR of 5.0%, according to a new report published by Grand View Research, Inc. Advancements in drug delivery systems are anticipated to drive the overall growth. In December 2017, Spark Therapeutics received Food and Drug Administration (FDA) approval for the first gene therapy drug in the ophthalmic market-Luxturna (voretigene neparvovec-rzyl). The drug is indicated for ophthalmic diseases associated with RPE65 gene mutation, such as retinitis pigmentosa and Leber’s congenital amaurosis. Increasing number of strategic mergers, acquisitions, and collaborations make the market for ophthalmic...
  2. 癌補助療法薬剤の世界市場：薬物クラス別
    GV9NV136 / Grand View Research / 2019年6月 / 当調査レポートでは、癌補助療法薬剤の世界市場について調査・分析し、市場動向、薬物クラス別（G-CSF、エリスロポエチン刺激剤（ESA）、制吐剤、ビスホスホネート、オピオイド、NSAIDおよびその他）分析、地域別分析、競合分析などを含め次の構成でお届け致します。 ・調査手法及び範囲 ・エグゼクティブサマリー ・市場動向 ・癌補助療法薬剤の世界市場：薬物クラス別（G-CSF、エリスロポエチン刺激剤（ESA）、制吐剤、ビスホスホネート、オピオイド、NSAIDおよびその他） ・癌補助療法薬剤の世界市場：地域別 ・競合分析 ...The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment. Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive...
  3. 抗凝固拮抗薬の世界市場2020-2026：薬物クラス別（プロトロンビン複合体濃縮物、凝固因子、モノクローナル抗体、フィトナジオン、その他）、地域別
    BZW20JN001 / Bizwit Research & Consulting / 2020年4月10日 / 本調査レポートでは、抗凝固拮抗薬の世界市場について調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、薬物クラス別（プロトロンビン複合体濃縮物、凝固因子、モノクローナル抗体、フィトナジオン、その他）分析、地域別分析、競争状況などを含め、次の構成でお届け致します。 ・エグゼクティブサマリー ・市場定義・範囲 ・市場動向 ・産業分析 ・抗凝固拮抗薬の世界市場：薬物クラス別（プロトロンビン複合体濃縮物、凝固因子、モノクローナル抗体、フィトナジオン、その他） ・抗凝固拮抗薬の世界市場：地域別 ・競争状況...Global Anticoagulant Reversal Drugs Market is valued approximately at USD 811.56 Million in 2019 and is anticipated to grow with a healthy growth rate of more than 15.6% over the forecast period 2019-2026. Anticoagulant drugs are medicines that has application in protection from blood clotting, used to reverse or balance bleeding. It is also helpful in prevention of risk related to the anticoagulants that arises due to the overdose of an anticoagulant therapy or unplanned surgery. It also prevents from serious conditions such as strokes and heart attacks to the individual suffering from blood clots. The anticoagulant reversal drugs have...
  4. 制酸薬の世界市場：薬物クラス別（プロトンポンプ阻害剤、H2拮抗薬、酸中和剤）、製剤別（錠剤、液体、粉末）、地域別予測
    BZW9OT005 / Bizwit Research & Consulting / 2019年9月 / 本資料は、制酸薬の世界市場について調べ、制酸薬の世界規模、市場動向、市場環境、薬物クラス別（プロトンポンプ阻害剤、H2拮抗薬、酸中和剤）分析、製剤別（錠剤、液体、粉末）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・制酸薬の世界市場概要 ・制酸薬の世界市場環境 ・制酸薬の世界市場動向 ・制酸薬の世界市場規模 ・制酸薬の世界市場規模：薬物クラス別（プロトンポンプ阻害剤、H2拮抗薬、酸中和剤） ・制酸薬の世界市場規模：製剤別（錠剤、液体、粉末） ・制酸薬の世界市場：地域別市場規模・分析...Antacid Market is valued approximately USD 6.13 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2019-2026. The growingincrease prevalence of gastric diseases has led the healthcare and pharmaceuticals providers towards the development of more enhanced gastric solution to get relief from acidity and heartburns. Antacids are the class of drugs thatwhich reduces gastric acidity resulting in the increase pH of the stomach and duodenum. The growing prevalence of gastric diseases among geriatric population has led to the increase in demand for antacids. The advancement of e-commerce industry...
  5. 気管支拡張薬の世界市場：薬物クラス別（交感神経刺激薬、抗コリン作用薬、ホスホジエステラーゼ阻害薬、配合剤）、疾患別（喘息、COPD、その他）、投与経路別（経口、注射、吸入器）
    AMR20MY0115 / Allied Market Research / 2020年2月 / 本調査レポートでは、気管支拡張薬の世界市場について調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、疾患別（喘息、COPD、その他）分析、薬物クラス別（交感神経刺激薬、抗コリン作用薬、ホスホジエステラーゼ阻害薬、配合剤）分析、投与経路別（経口、注射、吸入器）分析、地域別分析、企業概要などを含め、今後の方向性を明らかに致します。 ・イントロダクション ・エグゼクティブサマリ－ ・市場概要 ・気管支拡張薬の世界市場：疾患別（喘息、COPD、その他） ・気管支拡張薬の世界市場：薬物クラス別（交感神経刺激薬、抗コリン作用薬、ホスホジエステラーゼ阻害薬、配合剤） ・気管支拡張薬の世界市場：投与経路別（経口、注射、吸入器） ・気管支拡張薬の世界市場：地域別 ・企業概要...The global bronchodilators market was valued at $27,580.00 million in 2018 and is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Bronchodilators are drugs that relax muscles that tighten around the airways. These drugs open airways and allow more air to move in and out of lungs. They are also used to reduce mucus from lungs. Patients suffering from respiratory disorders consume these drugs through the help of nebulizers or inhalers. In addition, inhaler bronchodilators have effects on mucociliary clearance as well. Bronchodilators are used in the treatment of obstructive lung diseases...
  6. 歯科インプラントの世界市場：種類別（チタン、ジルコニウム）、地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA）
    GV20MY046 / Grand View Research / 2020年3月4日 / 本調査レポートでは、歯科インプラントの世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、種類別（チタン歯科インプラント、ジルコニア歯科インプラント）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東及びアフリカ）分析、競争分析などの構成でお届けいたします。 ・調査手法・範囲 ・エグゼクティブサマリー ・市場要因・動向・範囲 ・歯科インプラントの世界市場：種類別（チタン歯科インプラント、ジルコニア歯科インプラント） ・歯科インプラントの世界市場：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東及びアフリカ） ・競争分析...The global dental implants market size is expected to reach a value of USD 9.0 billion by 2027, registering a CAGR of 9.0% over the forecast period, according to a new report by Grand View Research, Inc. Rising demand for tooth replacement has provided good growth potential to the market. Increasing number of dental injuries owing to road accidents and sports injuries are some of the major factors boosting the demand. With growing aesthetic awareness, people are exploring more treatment options, which is leading to the growth of the market. For instance, as per the American Academy of Cosmetic Dentistry...
  7. アンドロゲン欠乏療法（ADT）の世界市場：薬物クラス別（抗アンドロゲン、LHRHアゴニスト、LHRH拮抗薬、その他）、投与経路別（経口、注射）、流通経路別（病院、小売薬局、オンライン薬局）、地域別
    BZW20AP030 / Bizwit Research & Consulting / 2020年2月6日 / 本調査レポートでは、アンドロゲン欠乏療法（ADT）の世界市場について、エグゼクティブサマリー、市場の定義・範囲、市場動向、産業分析、薬物クラス別（抗アンドロゲン、LHRHアゴニスト、LHRH拮抗薬、その他）分析、投与経路別（経口、注射）分析、流通経路別（病院、小売薬局、オンライン薬局）分析、地域別分析、競争状況などを総合的、多面的に調査・分析しております。 ・エグゼクティブサマリー ・市場の定義・範囲 ・市場動向 ・産業分析 ・アンドロゲン欠乏療法（ADT）の世界市場：薬物クラス別（抗アンドロゲン、LHRHアゴニスト、LHRH拮抗薬、その他） ・アンドロゲン欠乏療法（ADT）の世界市場：投与経路別（経口、注射） ・アンドロゲン欠乏療法（ADT）の世界市場：流通経路別（病院、小売薬局、オンライン薬局） ・アンドロゲン欠乏療法（ADT）の世界市場：地域別 ・競争状況...Global Androgen Deprivation Therapy (ADT) Market is valued approximately at USD XX billion in 2018 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2019-2026. Androgen deprivation therapy (ADT) is a type of antihormone therapy which is primarily utilized in the cure of prostate cancer. Prostate cancer cells typically requires androgen hormones such as testosterone to grow. The use of androgen deprivation therapy reduces the level of androgen hormones, with surgery or drug delivery to prevent the prostate cells from rising. Various studies have determined that ADT has shown the benefits...
  8. 抗リウマチ薬の世界市場：薬物クラス別（疾患修飾性抗リウマチ薬（DMARD）、非ステロイド性抗炎症薬（NSAID）、コルチコステロイド、尿酸薬、その他）、種類別（処方薬、市販薬）
    AMR20MY0123 / Allied Market Research / 2020年1月 / 本調査レポートでは、抗リウマチ薬の世界市場について調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、薬物クラス別（疾患修飾性抗リウマチ薬（DMARD）、非ステロイド性抗炎症薬（NSAID）、コルチコステロイド、尿酸薬、その他）分析、種類別（処方薬、市販薬）分析、地域別分析、企業概要などを含め、今後の方向性を明らかに致します。 ・イントロダクション ・エグゼクティブサマリ－ ・市場概要 ・抗リウマチ薬の世界市場：薬物クラス別（疾患修飾性抗リウマチ薬（DMARD）、非ステロイド性抗炎症薬（NSAID）、コルチコステロイド、尿酸薬、その他） ・抗リウマチ薬の世界市場：種類別（処方薬、市販薬） ・抗リウマチ薬の世界市場：地域別 ・企業概要...The global anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026. Rheumatoid arthritis (RA) is a chronic auto-immune disorder that majorly affects joints along with articular tissues and extra-articular organs. Furthermore, this medical condition is often progressive and results in pain, stiffness, and swelling of joints. Moreover, there is no permanent cure for RA, the goals of the treatment are to reduce pain, decrease inflammation, prevent bone deformity, and improve a person’s overall function. This is achieved through pain medication, steroids, and NSAIDs...
  9. 嚢胞性線維症（CF）治療薬の世界市場：薬物クラス別（膵酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター）、投与経路別（経口、吸入）
    AMR20JN031 / Allied Market Research / 2019年11月30日 / 本市場調査レポートでは嚢胞性線維症（CF）治療薬について、イントロダクション、エグゼクティブサマリー、市場概要、薬物クラス別（膵酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター）分析、投与経路別（経口、吸入）分析、地域別分析、企業概要に区分して収録しています。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・嚢胞性線維症（CF）治療薬の世界市場：薬物クラス別（膵酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター） ・嚢胞性線維症（CF）治療薬の世界市場：投与経路別（経口、吸入） ・嚢胞性線維症（CF）治療薬の世界市場：地域別 ・企業概要 ...The global cystic fibrosis therapeutics market was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. Cystic fibrosis is a progressive, hereditary disease that led to insistent lung infections and limits the patient’s ability to breathe over time. Diagnosis of cystic fibrosis is a multistep process, and includes a newborn screening, a sweat test, a genetic or carrier test, and a clinical evaluation. Though people diagnosed with the disease are of age of 2, some are also diagnosed as adults. A specialist can order a...
  10. 抗高脂血症薬の世界市場：薬物クラス別（スタチン、PCSK9阻害剤、胆汁酸封鎖剤、コレステロール吸収阻害剤、フィブリン酸誘導体、配合）
    AMR20FE019 / Allied Market Research / 2019年12月24日 / 本調査レポートでは、抗高脂血症薬の世界市場について調べ、イントロダクション、エグゼクティブサマリー、市場概要、薬物クラス別（スタチン、PCSK9阻害剤、胆汁酸封鎖剤、コレステロール吸収阻害剤、フィブリン酸誘導体、配合）分析、地域別分析、企業概要などを総合的、多面的にまとめております。 ・イントロダクション ・エグゼクティブサマリ－ ・市場概要 ・抗高脂血症薬の世界市場：薬物クラス別（スタチン、PCSK9阻害剤、胆汁酸封鎖剤、コレステロール吸収阻害剤、フィブリン酸誘導体、配合） ・抗高脂血症薬の世界市場：地域別 ・企業概要...The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, surge in level of lipids in the blood leads to their deposition in the arteries. This deposition of the lipids in the arteries leads to blockage, which in turn increases the risk of heart attacks. Therefore, the condition requires early detection...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆